BioFocus, a UK biotechnology company, will receive undisclosed fees from Organon for its role in the collaboration. The agreement is the second part of the company’s agreement with Organon, and it follows a successful screening collaboration.
Geoff McMillan, BioFocus’ chief executive, commented: “We have enjoyed a fruitful collaboration with Organon over the past year, and now look forward to expanding our relationships with them. BioFocus is proud to be a preferred supplier of drug discovery services for this world class company.”
BioFocus was founded in 1997, and is now well established within the industry in the key area of drug discovery.
Organon products are sold in over 100 countries, of which more than 60 have an Organon subsidiary. The company is the human health care business unit of Akzo Nobel.